Yaohua Pharmaceutical s revenue in January increased by 118 year on year! U.S. sales of needles show

Mondo Finance Updated on 2024-02-06

Yaohua Pharmaceutical announced today that its January revenue was 5100 million yuan, a monthly decrease of 248%, an annual increase of 118%. Yaohua said that the monthly decrease was due to the lack of shipments in Europe, and the annual increase was due to a double-digit increase in the number of needles sold in the United States to benefit from the new rare blood cancer drug Ropeginterferon ALFA-2B (ROPEG, i.e. P1101), and the price of Ropeg in the United States increased slightly in January.

After the new team joined Yaohua Pharmaceutical USA, the sales strategy of digital AI big data and the recommendation of NCCN** guidelines promoted the double-digit growth of Ropeg's sales in the United States, but because the U.S. medical insurance system recalculates the patient's deductible at the beginning of each year, the revenue of the pharmaceutical company at the beginning of the year will be slightly affected, and if you look at it quarterly, the growth trend this year is clear.

Yaohua Pharmaceutical pointed out that Japanese patients can self-inject ROPEG since June this year, and they can take a 3-month supply at a time, because ROPEG has been included in the Japanese medical insurance payment, which can reduce the amount of patients' out-of-pocket payments, which is very helpful to increase the number of patients and expand the market.

ROPEG is expected to obtain polycythemia vera (PV) drug licenses in China, Singapore and Malaysia this year, and enter the Chinese and Southeast Asian markets, and is now actively planning marketing preparations, and ROPEG's global sales growth is expected to be upward, and the management team led by Chairman Zhan Qingliu and CEO Lin Guozhong to visit subsidiaries in the United States, Japan, South Korea and other subsidiaries to actively plan and prepare for the next wave of operational growth.

First picture**: Science and Technology News).

Related Pages